Picture of Beximco Pharmaceuticals logo

BXP — Beximco Pharmaceuticals Share Price

0.000.00%
gb flag iconLast trade - 00:00
HealthcareAdventurousSmall CapContrarian

Momentum

Relative Strength (%)
1m-9.11%
3m-24.49%
6m-34.11%
1yr-15.69%
Volume Change (%)
10d/3m-5.76%
Price vs... (%)
52w High-47.33%
50d MA-15.04%
200d MA-27.99%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)5.63
PEG Ratio (f)0.17
EPS Growth (f)49.71%
Dividend Yield (f)4.23%
Valuation (ttm)IndustryMarket
Price to Book Value0.86
Price to Tang. Book0.99
Price to Free Cashflow10.9
Price to Sales1.02
EV to EBITDA6.8

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital13.61%
Return on Equity15.23%
Operating Margin21.31%

Financial Summary

Year End 30th JunUnit201720182019202020212022E2023ECAGR / Avg
Total RevenueBDTm15,508.7817,716.7222,816.6325,611.9529,493.5725,944.5834,861.58.04%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%-28+13.79+19.6+16.76+45.16-20.86+49.71n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Jun 202230th Jun 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Beximco Pharmaceuticals EPS forecast chart

Profile Summary

Beximco Pharmaceuticals Limited (BPL) is engaged in the manufacturing and marketing of generic pharmaceutical formulation products, including intravenous fluids and active pharmaceutical ingredients (APIs). The Company also provides contract manufacturing services. The Company produces different presentations, and the portfolio encompasses various key therapeutic categories, including antibiotics, analgesics, anti-diabetics, respiratory, cardiovascular, central nervous system, dermatology, and gastrointestinal. Its product categories also include anti-infectives, musculoskeletal, oncology, respiratory, skin care, vitamins and mineral supplements, and others. The Company's products include Acifix, Femzole, Q-Rash, Tamona, Taverin, Tobasol, IcyKool Cream, Intracef, Gastalfet, Iprasol, Calorate, Gentosep, and others. BPL's products are sold in domestic and international markets.

Directors

Last Annual
June 30th, 2021
Last Interim
March 31st, 2022
Incorporated
December 31st, 1976
Public Since
October 21st, 2005
No. of Employees
2,310
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
gb flag iconLondon Stock Exchange
Shares in Issue
446,112,089

BXP Share Price Performance

Similar to BXP

Picture of Abcam logo

Abcam

gb flag iconLondon Stock Exchange

Picture of Alliance Pharma logo

Alliance Pharma

gb flag iconLondon Stock Exchange

Picture of Animalcare logo

Animalcare

gb flag iconLondon Stock Exchange

Picture of AstraZeneca logo

AstraZeneca

gb flag iconLondon Stock Exchange

Picture of Benchmark Holdings logo

Benchmark Holdings

gb flag iconLondon Stock Exchange

FAQ

Or unlock with your email

Or unlock with your email